UltraSight (formerly OnSight Medical), a Tel Aviv, Israel-based digital health company focused on cardiac imaging, raised $13M in Series B funding.
The round was led by Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science.
The company intends to use the funds to advance U.S. clinical programs for its real time, AI guidance in a variety of care settings.
Led by Davidi Vortman, CEO, UltraSight provides an AI platform for ultrasound devices to conduct sonography at the point of care. Point of care ultrasound allows medical professionals to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings.